大肠癌组织中EGFR、c-erbB-2、CD44V6和p53异常表达与3年生存率分析

目的：同时检测癌基因EGFR、c-erbB-2、CD44v6和p53在大肠癌组织中的异常表达，分析不同表达水平患者组的3年生存率差异。方法：对63例存档大肠癌石蜡组织标本进行重新切片，分别采用EGFR、c-erbB-2、CD44v6和p53单克隆抗体进行免疫组化染色（SABC法）。所有病例均随访3年以上。结果：全部63例大肠癌中除4例（6．3％）无任何1种癌基因蛋白表达外，11例（17．5％）表达1种癌基因蛋白的患者3年生存率88．8％；19例（30．2％）表达2种癌基因蛋白的患者3年生存率70．5％；15例（23．8％）表达3种癌基因蛋白的患者3年生存率57．8％；14 例（22．2％）表达全部4种癌基因蛋白患者3年生存率22．2％，与前3组患者的3年生存率比较均有显著性差异（P＜0．01）。结论：同时检测大肠癌组织4种癌基因蛋白异常表达可准确判断患者不良预后。

The 3-Year Survival Rate of Colorectal Cancers with EGFR, c-erbB-2, CD44v6 and p53 Expressions

Objective:To investigate the3-year survival rate of colorectal cancers which have the co-expression of EGFR,c-erbB-2,CD 44 v6and p53proteins.Methods:Expressions of EGFR,cerbB-2,CD 44 v6and p53were detected with four monoclonal antibodies respectively by immunohistochemical SABC staining in63colorectal cancers.All the patients were followed up for42months.Results:Except 4(6.3%)patients with none of EGFR,c-erbB-2,CD 44 v6and p53expressions;the3-year survival rates of11(17.5%)patients with one expression,19(30.2%)patients with two expressions,15(23.8%)patients with three expressions and14(22.2%)patients with all four expressions were88.8%,70.5%,57.8%and22.2%respectively.The last rate was significantly lower than the former three rates(P<0.01).Conclusion:Detection of these four ex-pressions simultaneously may be helpful for assessing the patient with colorectal cancer being at greater risk of poor prognosis.